Generis, a UK-based content and information management systems provider for regulated industries, has announced a strategic partnership with Cognizant, a global provider of information technology, consulting, and business process services, to deliver innovative information management solutions for Life Sciences.
Generis partners with Cognizant to expand global presence
This partnership will see Cognizant leverage Generis' flagship product, the CARA Life Science Platform, to enable clients to streamline their business processes on one comprehensive Workspace that covers: RIM / Regulatory and Quality / QMS and Safety / PV and Clinical, as well as enterprise-wide functionality such as Component-Based / Structured Content Authoring.
CARA is an innovative enterprise workspace designed specifically for Life Sciences which offers a simple, unified way of working with business-critical content and information. The solution enables rapid, codeless implementation of regulated business processes for managing content and data securely and seamlessly across the business, with connectivity to modern productivity tools (e.g., Office 365, DocuSign, Slack, Google Docs/Drive, SAP and many others). With a standardisation of processes across the business, CARA allows organisations to ensure consistent rules for security, versioning, lifecycles and workflows. The platform delivers secure, versatile and scalable solutions both in the cloud as SaaS or on premise.
Generis CEO James Kelleher said: “We are delighted to be working with such a forward-thinking organisation. Cognizant understands the business problems that our mutual customers face, and how to address those in a way that goes beyond the standard IT implementation partner approach. This strategic partnership will enable our existing and new customers to make the most of the possibilities within the CARA platform.”
CARA is already widely deployed in the pharmaceutical, biotech, medical device, and other Life Sciences industries where strict regulatory compliance must be maintained.
Customers include 60 per cent of the Top 20 largest global life science companies as well as over 500,000 users globally.